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1. Introduction
Psoriasis is a chronic disease which affects 1 to 3% of different ethnic populations [1]. As
well as the size of the affected population, the social and emotional burden brought by the
stigmatization of psoriasis caused serious innovation to the pathogenesis and treatment of
the disease.
The majority of the current data about psoriasis is about immune system elements and role
of inflammation in the pathogenesis. The development of psoriasis is associated with genetic
predisposition which has a basis of T cell activation secondary to dermal inflammation with
abnormal keratinocyte proliferation. Tumor necrosis factor alpha (TNF-α), interferon gama
(IFN-γ), and interleukin (IL)-8 which are secreted by T lymphocytes, keratinocytes and in‐
flammatory cells polarize type 1 T lymphocytic pathway and lead to the migration of poly‐
morphonuclear leukocytes to the epidermis predominantly [2]. Upregulation of HLADR,
intercellular adhesion molecule-1 and E-selectin activates CD2+, CD3+, CD5+, CLA+,
CD45RO, HLA-DR, CD25 (IL-2 receptor) and CD27 expressing T cells [2]. Migration and ac‐
cumulation of inflammatory cells in the epidermis destroyes the basal membrane and des‐
mosomes. In response to the damage, mitogenic cyokines are secreted and a similar process
to wound healing results in rapid cell cycling and rapid maturation of keratinocytes [1, 2,
3].The constant inflammatory cell chemotaxis and cytokine release causes the chronic clini‐
cal course with recurrent lesions.
Inflammation is described as a complex physiologic defense mechanism consisting of local
changes in hemodinamy, increase in microvascular permeability and a series of intracellular
reactions [4]. The autoimmune connective diseases are mainly defined as the prototype of
inflammatory diseases. Recently, atherosclerosis, obesity and diabetes mellitus are included
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in inflammatory disease category because they are also proved to cause secondary tissue
damage by inflammatory mechanisms [4, 5].
In psoriasis, T cells together with their cytokines and chemokines are shown to induce seri‐
ous inflammation by Th1- and Th17-driven immune response including IL-20, IL-23, IL-12,
IL-17 and IL-22 [2, 3, 4, 5]. Lately psoriasis is assumed as an immune mediated inflammato‐
ry disease and psoriatic patients are exposed to the systemic effects of the inflammation [5].
2. Psoriasis as a systemic disease
Psoriatic patients were shown to have inceased levels of circulating Th1-type cytokines,
soluble adhesion molecules, vascular endothelial growth factor (VEGF), epidermal growth
factor (EGF) and acute phase reactants [2, 3, 4, 5, 6]. As a systemic inflammatory disease,
more specific and sensitive markers are thought to be beneficial in monitorizing the system‐
ic inflammation observed in psoriasis where they can be used to predict the development
risk of secondary inflammatory diseases; psoriatic comorbidities.
The comorbidities of psoriasis are listed as obesity/metabolic syndrome, autoimmune dis‐
eases, psychiatric diseases, cardiovascular diseases, sleep apnea, cancer/lymphoma, non-al‐
coholic steatohepatitis (NASH) and chronic obstructive pulmonary disease (COPD) [7, 8, 9,
10, 11, 12]. In this chapter, the comorbidities which are especially related with systemic in‐
flammation of psoriasis will be discussed in more detail.
2.1. Psoriasis and systemic inflammatory markers
The studies conducted for the definition of inflammatory process of psoriasis helped to per‐
form the exact measurements for proinflammatory cytokines such as IL-1 and TNF-α, adhe‐
sion molecules as intracellular adhesion molecule-1 (ICAM-1) and selectines, IL-6 and
hepatic acute phase reactants as C reactive protein (CRP) [13, 14].
CRP testing is particularly important and it is also been proved to be risk predictor for the
development of cardiovasculary diseases [15, 16, 17, 18].
2.1.1. C reactive protein
C reactive protein was first defined by Tillett and Francis as a protein developed against
carbonhydrate  component  of  streptococcus  pneumonia  capsule  in  the  serum of  patients
with pneumonia and named as carbonhydrate reactive protein [19]. CRP is a non-glycol‐
ised pentameric protein made by hepatocytes with a molecular weight of 118 kilodaltons
(kD). The molecule is known as a major acute phase reactant which increases rapidly af‐
ter infections or tissue damage, widely used as a laboratory parameter for the follow-up
of  inflammatory  and  infectious  disease  activity  and  is  accepted  as  a  very  sensitive  in‐
flammatory marker [17, 18, 19]. Blood levels of CRP can increase 100 times in the first 24
hours  and  can  decrease  to  normal  levels  soon  after  treatment  or  spontaneous  healing.
Therefore  CRP is  a  valuable  laboratory  parameter  for  infections,  tissue  damage and in‐
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flammation.  Standard measurements of  CRP levels  can detect  plasma levels  of  3-8  mg/l
CRP levels and healthy individuals have blood levels of CRP under 2 mg/l. New labora‐
tory methods for the measurement of CRP have been developed and these sensitive CRP
measurements  can  detect  lower  levels  of  CRP which  are  significantly  related  to  certain
inflammatory diseases and cardiovascular diseases[16, 17, 18, 19].
The synthesis of CRP is mainly controlled by IL-6 but IL-1 and TNF-α may influence CRP
levels as well and increase of CRP in blood and other body fluids is a constant result of these
proinlammatory cytokines [15,16]. In this aspect, serum CRP is an indirect marker of proin‐
flammtory cytokine activity. As a fact, CRP plays a role in host’s immune defense. It binds
to the phosphocoline on the surface of the microorganisms preparing them for phagocytosis
and lysis. It also activates complement system by binding to LDL on atherosclerotic plaques
and induces inflammation [15, 16]. CRP is also shown to increase the expression of tissue
factor on macrophages resuting trombosis. As a classic acute phase marker, CRP induces
monocyte-macrophage migration, expression of tissue factor with adhesion molecules and
monocyte chemotactic protein-1 [15, 16, 17]. By all of these features, CRP is assumed to in‐
crease ischemic myocard damage by participating aterosclerotic pathogenesis.
CRP levels raise as a part of ischemia related acute phase response. Among the plasma
markers, CRP is widely used to assess cardiovascular risk. Highly sensitive methods of CRP
measurements showed that even levels of CRP within normal ranges may have predictive
value in acute coronary syndromes. Sensitive CRP levels are found significantly high when
ruptured aterom plaques exist. Recent studies also reveal that there is a strong independent
relationship between CRP and future cardiovascular events. American Heart Association
and Center for Disease Control (CDC) reported that sensitive CRP is a risk marker for coro‐
nary artery diseases [19, 20, 21, 22, 23, 24].
Recent studies showed that psoriatic patients have increased CRP levels and it  was also
suggested that psoriasis is a systemic inflammatory disease preparing a convenient envi‐
ronment  for  cardiovascular  diseases  and  comorbidities.  The  theraupatic  modalities  of
psoriasis  are  also  started to  be  investigated for  their  efficacies  for  lowering CRP levels.
Metothrexate (MTX) is  found to be efficient  in decreasing CRP levels  in rheumatoid ar‐
thritis  (RA)  [25,  26].  In  fact,  MTX therapy reduced the  incidence  of  vascular  disease  in
patients  with psoriasis  or  RA and it  was hypothesized that  this  effect  is  caused by the
drug’s  anti-inflammatory  property  [27].  Cyclosporine  was  efficient  as  metothraxate  and
etanercept in decreasing CRP levels in psoriatic  arthiritis  [26,  28].  In a recent study, pa‐
tients  with  higher  sensitive  CRP levels  were  found to  have  a  better  response  to  cyclo‐
sporine therapy [29].  TNF-α inhibitors managed to decrease CRP levels in patients with
psoriasis and RA [30, 31]. However, in a meta-analysis investigating association between
biologic  therapies  and  cardiovascular  events,  there  was  no  significant  difference  in  the
rate  of  major  cardiovascular  events  observed  in  patients  receiving  anti-IL-12/IL-23  anti‐
bodies or anti-TNF-α treatments compared with placebo [32].
Effective treatment of severe psoriasis is thought to be crucial in avoiding systemic inflam‐
matory response although not determined precisely. Therefore psoriatic therapies must also
aim the control of a systemic inflammatory disease which is accepted as a predisposition to
Psoriasis: A Disease of Systemic Inflammation with Comorbidities
http://dx.doi.org/10.5772/54347
109
cardiovasculary diseases. As well as to obtain healthy skin barier and to increase the severe‐
ly impaired quality of life, the monitorization and control of systemic inflammation must be
aimed. CRP seems to promise an efficient option for this aim.
2.1.2. Other inflammatory markers
In addition to CRP, there are a few investigated serum inflammatory markers in psoriasis.
Serum amyloid A (SAA) protein is the precursor of amyloid fibrils which deposit in secon‐
dary amyloidosis. It is primerely synthesized as an acute inflammatory reactant from the liv‐
er with a molecular weight of 11685 D. Acute inflammatory markers are known to be
regulated by hormones, cytokines derived from adipose tissue and synthesized in liver [33,
34]. Adipose tissue is known as the most important source of IL-6 in body and accepted to
play a key role in SAA and CRP synthesis. SAA release is likewise increased by IL-1, IL-6
and TNF- α. SAA has a wide level range, it raises rapidly and decreases so soon after infec‐
tions and enables to represent the acute inflammatory process better than CRP [36]. SAA is a
protein which is also a member of high density lipoproteins (HDL) and is synthesized as the
predominant apolipoprotein on the plasma HDL particules within the acute inflammatory
process. SAA is also produced by synovial fibroblasts and induce colleganase. Immune sys‐
tem cells are attracted by SAA to related sites of inflammation [37].
Inflammatory reactants are released in a coordinated order with systemic and metabolic
changes as a response to tissue damage and infection. SAA is a major component of acute
inflammatory response. In a similar way to CRP, SAA rises in the serum after infection, in‐
flammation, tissue damage and stress. It is shown to raise in chronic infectious diseases like
tuberculosis, lepra, in autoimmune diseases like RA and systemic lupus erythematosus, in
kidney transplant rejection, benign monoclonal gammopathy and malign diseases [17, 37].
The increased SAA within acute inflammatory process replaces with apolipoprotein A-1 and
decreases the HDL mediated cholesterole entry to the liver cells which is supported by in‐
ceased levels of SAA in coronary artery disease patients. High sensitive CRP and SAA are
related with vasculary wall inflammation and accepted as predictors of coronary vascular
events. In a study in 1999 SAA is found as an independent risk factor for cardiovasculary
diseases [37]. In another study SAA was found as a strong predictor for cardiovasculary dis‐
eases [22, 37, 38]. In a recent study involving severe psoriatic patients, SAA was found sig‐
nificantly higher in patients with severe psoriasis compared to a sex and age matched
control group [39].
Other inflammatory markers recently investigated in psoriasis are platelet-derived micro‐
particles, soluble P-selectin, adiponectins, lectins, haptoglobins, ceruloplasmin, α1- antitryp‐
sin, chitinase 3-like protein 1 (YKL-40, CHI3L1) and serum lipocalin-2 [40, 41, 42, 43].
2.2. Psoriasis and comorbidities
Diseases included as psoriatic comorbidities are obesity/metabolic syndrome, autoimmune
diseases, psychiatric diseases cardiovascular diseases, sleep apnea, cancer/lymphoma,
Psoriasis - Types, Causes and Medication110
NASH and COPD. In this chapter, the systemic inflammation related comorbidities of psor‐
iasis will be discussed.
2.2.1. Psoriasis and obesity/metabolic syndrome
Adipose tissue is known as the most important source of IL-6 in body. Inflammation is
mainly controlled by hormones, cytokines derived from adipose tissue and liver by IL-1,
IL-6 and TNF- α. Common cytokine pathways are responsible for both psoriasis and obesity
but it is yet to be answered which pathology comes first when psoriasis-associated obesity
and the metabolic syndrome is considered. It is also not revealed if the diseases are concur‐
rent in a convenient genetic background [44, 45, 46].
Obesity  and  metabolic  syndrome  are  correlated  with  increased  risk  for  coronary  heart
disease. The metabolic syndrome is in fact a group of risk factors which are listed as in‐
sulin resistance or glucose intolerance, abdominal/visceral obesity, dyslipidemia (high tri‐
glycerides, low HDL-C, high LDL-C), elevated blood pressure, prothrombotic state ( high
fibrinogen  or  PAI-1)  and  proinflammatory  state  (elevated  CRP,  TNF-  α,  IL-6).  Several
components of  metabolic  syndrome has been shown to be frequent in psoriatic  patients
[47].  In  a  study of  581  moderate-severe  psoriasis  patients,  an  increased prevalence  was
found for metabolic syndrome (OR=5.29), psoriasis patients were more likely to have dia‐
betes  mellitus,  hypertension,  hyperlipidemia,  coronary heart  disease and they were also
more likely to be smokers [48].
Despite the well documentation in adults, there is a few data for obesity/metabolic syn‐
drome in pediatric psoriasis patient population. Augustin et al found a higher prevalence of
hyperlipidemia, diabetes, hypertension and obesity in children with psoriasis than the con‐
trols retropectively [49]. Koebnick et al showed a significant association between increasing
weight and psoriasis in children in a cross-sectional study [50]. In a study by Au et al it was
suggested that metabolic syndrome occurs more frequently in pediatric patients with psor‐
iasis [51]. It is assumed that children with psoriasis have excess adiposity and are at risk for
associated complications.
2.2.2. Psoriasis and cardiovascular diseases
Recent studies show that local and systemic inflammation plays a big role in the patho‐
genesis of coronary artery diseases (CAD). Bhagat and Vallance has shown that TNF- α
and IL- 1 causes a transient reversible endothelium disfunction in humans [13]. High lev‐
els of IL- 6 and soluable IL- 2 are shown to be associated with impaired microvasculary
functions.  A  big  part  of  TNF-  α  induced  mechanisms  causes  endothelium  disfunction.
TNF- α raises  the  expression of  adhesion molecules.  After  the  exposition of  endothelial
cells to TNF- α, polimorphonuclear cells migrate to vasculary structures. In fact, TNF- α
supports the adhesion and invasion of dendritic cells to vascular walls.  After the induc‐
tion  of  the  dendritic  cells,  T  cells,  monocytes  and  macrophages  get  activated  and  pro‐
duce inflammation by cytokine production. High levels of TNF- α stimulates nitric oxide
synthase (NOS) in human endothelium cells.  This molecule is known to cause free radi‐
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cal production in neutrophils, smooth muscle cells in the vessels and endothelium. TNF-
α  induced  oxidative  stress  causes  the  apopitosis  of  endothelial  cells  [13,14].  All  of  this
data  shows that  endothelial  cells  are  the  target  of  cytokines  and other  vessel  cells.  The
prolonged exposition of  endothelial  cells  to inflammatory cytokines and oxidative stress
results in acceleration of apopitosis, development of trombus and formation of ateroscler‐
otic plaque.
Patients with psoriasis have an increased prevalence of risk factors for CAD. Psoriatic pa‐
tients who are characterised with elevated TNF- α levels have a significant higher frequency
of CAD, pulmonary emboli and cerebrovasculary diseases [52, 53, 54, 55].
Patients with moderate to severe psoriasis have an increased prevalence of CAD and an in‐
creased risk for myocardial infarction. In a cohort study by Ahlehoff et al, patients with
psoriasis showed a disease severity-dependent increased risk of ischaemic stroke and there
was an association between psoriasis and atrial fibrillation [54]. In a cohort study of general
practice research database, severe psoriasis was found as a risk factor for major adverse car‐
diac events (hazard ratio 1.53; 95% confidence interval, 1.26-1.85) after adjusting for age,
gender, diabetes, hypertension, tobacco use, and hyperlipidemia. Severe psoriasis added
6.2% absolute risk of major adverse cardiac events.[55] Gelfand et al used the General Prac‐
tice Research Database (GPRD) to determine if psoriasis is an independent risk factor for
myocardial infarction. The study included 3827 (2.9%) severe psoriatic patients with a mean
follow-up period of 5.4 years. A significant relationship was shown between the cardiovas‐
culary disease risk and psoriasis duration and severity. An increased incidence of acute my‐
ocardial infarction (AMI) in patients with psoriasis was found and the AMI rate was highest
in patients with severe psoriasis [56]. Psoriatic patients had a x2.6 increased risk for occlu‐
sive vasculary disease and x1.6 increased risk for venous occlusion compared to healthy
population Psoriatic patients are also shown to have increased levels of aterotrombotic
markers like fibrinogen and plasminogen activator inhibitor-1 (PAI-1) [57].
As well as systemic inflammation, other possible suggested mechanisms for CAD comorbid‐
ity of psoriasis are increased prevalence of common CAD risk factors in psoriasis patients
and antipsoriatic medications are suspected (cyclosporine, acitretin) for their adverse CAD
risk profiles (e.g., elevation of blood pressure, elevation of serum levels of lipids).
3. Conclusion
Psoriasis is associated with multiple CAD risk factors. In fact it is suggested as an independ‐
ent risk factor for CAD. Obesity and metabolic syndrome are also common in both pediatric
and adult psoriatic patients. As a systemic inflammatory disease with important life threat‐
ening comorbidities, there is a need for a systematic and complementary understanding of
medical care for psoriasis. Screening guidelines for especially severe psoriatic patients has to
be reviewed for susceptibility risk factors for the common comorbidities. The approach to
psoriasis may also include not only dermatology but also cardiology, rheumatology, and en‐
docrinology assessments at certain points.
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